CVRx, Inc.
CVRXCVRx is a commercial-stage medical device company that develops and manufactures minimally invasive neuromodulation solutions for cardiovascular disease.
Earnings
Next report
Aug 6, 2026 (In 1 week)Valuation & ratios
Competitors
By market cap
By revenue growth
By net margin
Profile
CVRx is a commercial-stage medical device company that develops and manufactures minimally invasive neuromodulation solutions for cardiovascular disease. Its core value proposition is the Barostim system, the first FDA-approved technology that uses electrical pulses to activate baroreceptors, balancing the autonomic nervous system to treat heart failure symptoms. The therapy is designed to complement standard pharmaceutical treatments for patients who remain symptomatic despite guideline-directed medical therapy.
CVRx holds a first-mover advantage as the provider of the only FDA-approved neuromodulation device for heart failure symptoms, supported by a significant body of clinical evidence and FDA Breakthrough Device designation.
Questions, answered.
- What is CVRx, Inc.'s market cap?
- CVRx, Inc. (CVRX) has a market capitalization of $129.5M and trades on NASDAQ.
- What is CVRx, Inc.'s revenue and profitability?
- CVRx, Inc. generated $59.1M in trailing twelve-month revenue with a net loss of $52.7M, representing a net margin of -89.1%. Gross margin stands at 86.2%, with free cash flow of -$40.2M. These figures are based on the Q1 2026 filing.
- Who are CVRx, Inc.'s competitors?
- CVRx, Inc.'s key competitors include Boston Scientific, Abbott Laboratories, Medtronic, and others. These companies compete in similar markets and product categories.
- Who does CVRx, Inc. partner with?
- CVRx, Inc.'s notable partners include Centers for Medicare and Medicaid Services.
- Where is CVRx, Inc. headquartered?
- CVRx, Inc. is headquartered in United States of America and employs approximately 200 people. It has been publicly traded since 2021.
